Share Price and Basic Stock Data
Last Updated: November 28, 2025, 11:10 am
| PEG Ratio | 0.52 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Fortis Malar Hospitals Ltd operates within the Hospitals & Medical Services industry, focusing on healthcare delivery. The company’s share price stood at ₹64.6, with a market capitalization of ₹121 Cr. Over recent quarters, Fortis Malar’s revenue has demonstrated volatility. For instance, sales for June 2022 were ₹20.10 Cr, peaking at ₹23.29 Cr in September 2022, before declining to ₹17.76 Cr by June 2023. This downward trend continued into the first quarter of FY 2025, with sales plummeting to ₹5.52 Cr. The total sales for FY 2024 were reported at ₹59.01 Cr, a significant reduction compared to ₹85.95 Cr in FY 2023 and ₹86.18 Cr in FY 2022. The decline in revenues reflects challenges faced by the hospital sector, potentially exacerbated by competition and operational inefficiencies.
Profitability and Efficiency Metrics
Fortis Malar’s profitability metrics indicate significant challenges. The company reported an operating profit margin (OPM) of -1,650.00% for June 2025, an alarming figure that reflects operational inefficiencies. In FY 2024, the OPM was -2.05%, while in FY 2023, it was 5.32%, suggesting a steep decline in profitability. The net profit for FY 2024 was ₹45.32 Cr, a recovery from a loss of ₹15.48 Cr in FY 2023, indicating some positive operational adjustments. However, the net profit margin remained at 0.00% for FY 2025, indicating a complete halt in profitability. The interest coverage ratio (ICR) stood at a strong 56.70x, suggesting that the company can comfortably meet its interest obligations, although this may not compensate for the negative operational performance.
Balance Sheet Strength and Financial Ratios
Fortis Malar’s balance sheet presents a mixed picture. The company has no reported borrowings or reserves, indicating a lack of leverage but also a potential weakness in terms of capital structure. The price-to-book value (P/BV) stood at 4.56x, suggesting that the market values the company significantly higher than its book value, which was reported at ₹16.11 per share in FY 2025. The current ratio was a robust 5.15, indicating strong short-term liquidity. However, the cash conversion cycle remained challenging, with a CCC of -539.47 days in FY 2023, reflecting inefficiencies in cash management and inventory turnover. Furthermore, the return on equity (ROE) was reported at a meager 0.56%, indicating that shareholder equity is not being effectively utilized to generate profits.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Fortis Malar Hospitals Ltd reveals a significant concentration of ownership among promoters, who held 62.71% of the company as of December 2023. The public held a smaller share of 37.21%, while domestic institutional investors (DIIs) accounted for a mere 0.07%. The number of shareholders increased to 27,644 by March 2025, indicating growing interest from retail investors. However, the low DII participation may suggest a lack of confidence from institutional investors regarding the company’s future prospects. This could impact the stock’s liquidity and overall market perception. The high promoter holding coupled with low institutional investment may result in increased volatility, as institutional investors typically provide stability in share price movements.
Outlook, Risks, and Final Insight
Looking forward, Fortis Malar Hospitals faces several challenges and opportunities. The recovery of profitability hinges on the ability to manage operational costs and improve service delivery efficiency, particularly given the reported negative operating margins. Additionally, the company must address its cash management issues to improve its cash conversion cycle. Risks include the potential for continued revenue decline if market conditions do not improve and the challenges posed by a competitive healthcare landscape. On the upside, a strong interest coverage ratio provides a buffer against financial distress, and a potential recovery in patient volumes could improve revenues. In a scenario where operational efficiencies are realized, Fortis Malar could return to profitability, enhancing shareholder value significantly.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Fortis Malar Hospitals Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| NG Industries Ltd | 43.0 Cr. | 128 | 195/125 | 8.79 | 117 | 2.72 % | 23.6 % | 20.7 % | 10.0 |
| Global Longlife Hospital and Research Ltd | 20.2 Cr. | 19.2 | 35.5/18.3 | 24.3 | 0.00 % | 13.7 % | 17.7 % | 10.0 | |
| Gian Lifecare Ltd | 11.6 Cr. | 11.2 | 21.4/11.2 | 128 | 19.1 | 0.00 % | 3.00 % | 0.81 % | 10.0 |
| Fortis Malar Hospitals Ltd | 120 Cr. | 63.8 | 98.7/53.6 | 26.4 | 18.3 | 0.00 % | 0.83 % | 0.56 % | 10.0 |
| Family Care Hospitals Ltd | 20.6 Cr. | 3.81 | 7.60/3.40 | 1.51 | 0.00 % | 79.2 % | 85.5 % | 10.0 | |
| Industry Average | 27,787.29 Cr | 790.25 | 98.90 | 99.39 | 0.32% | 15.48% | 14.81% | 9.04 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 20.10 | 23.29 | 21.90 | 20.66 | 17.76 | 18.15 | 17.58 | 5.52 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 |
| Expenses | 20.13 | 21.01 | 20.30 | 19.93 | 18.27 | 18.23 | 18.67 | 5.04 | 0.88 | 0.47 | 0.41 | 0.37 | 0.35 |
| Operating Profit | -0.03 | 2.28 | 1.60 | 0.73 | -0.51 | -0.08 | -1.09 | 0.48 | -0.88 | -0.47 | -0.41 | -0.37 | -0.33 |
| OPM % | -0.15% | 9.79% | 7.31% | 3.53% | -2.87% | -0.44% | -6.20% | 8.70% | -1,650.00% | ||||
| Other Income | 1.64 | 1.50 | 1.52 | 1.97 | 1.61 | 2.31 | 1.26 | 59.69 | 0.83 | 0.56 | 0.56 | 0.77 | 4.61 |
| Interest | 1.55 | 1.61 | 1.49 | 1.42 | 1.35 | 1.30 | 1.26 | 0.39 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 3.02 | 2.91 | 2.78 | 3.44 | 2.67 | 2.72 | 2.91 | 1.06 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | -2.96 | -0.74 | -1.15 | -2.16 | -2.92 | -1.79 | -4.00 | 58.72 | -0.06 | 0.09 | 0.15 | 0.40 | 4.28 |
| Tax % | 0.00% | 491.89% | 0.00% | 223.15% | 0.00% | 0.00% | 0.25% | 7.95% | 0.00% | 0.00% | 93.33% | 10.00% | 3.04% |
| Net Profit | -2.96 | -4.38 | -1.15 | -6.99 | -2.93 | -1.79 | -4.00 | 54.05 | -0.06 | 0.09 | 0.01 | 0.36 | 4.15 |
| EPS in Rs | -1.58 | -2.34 | -0.61 | -3.73 | -1.56 | -0.96 | -2.13 | 28.84 | -0.03 | 0.05 | 0.01 | 0.19 | 2.21 |
Last Updated: August 19, 2025, 3:29 pm
Below is a detailed analysis of the quarterly data for Fortis Malar Hospitals Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 0.02 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2025) to 0.02 Cr., marking an increase of 0.02 Cr..
- For Expenses, as of Jun 2025, the value is 0.35 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.37 Cr. (Mar 2025) to 0.35 Cr., marking a decrease of 0.02 Cr..
- For Operating Profit, as of Jun 2025, the value is -0.33 Cr.. The value appears strong and on an upward trend. It has increased from -0.37 Cr. (Mar 2025) to -0.33 Cr., marking an increase of 0.04 Cr..
- For OPM %, as of Jun 2025, the value is -1,650.00%. The value appears to be declining and may need further review. It has decreased from 0.00% (Mar 2025) to -1,650.00%, marking a decrease of 1,650.00%.
- For Other Income, as of Jun 2025, the value is 4.61 Cr.. The value appears strong and on an upward trend. It has increased from 0.77 Cr. (Mar 2025) to 4.61 Cr., marking an increase of 3.84 Cr..
- For Interest, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Depreciation, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 4.28 Cr.. The value appears strong and on an upward trend. It has increased from 0.40 Cr. (Mar 2025) to 4.28 Cr., marking an increase of 3.88 Cr..
- For Tax %, as of Jun 2025, the value is 3.04%. The value appears to be improving (decreasing) as expected. It has decreased from 10.00% (Mar 2025) to 3.04%, marking a decrease of 6.96%.
- For Net Profit, as of Jun 2025, the value is 4.15 Cr.. The value appears strong and on an upward trend. It has increased from 0.36 Cr. (Mar 2025) to 4.15 Cr., marking an increase of 3.79 Cr..
- For EPS in Rs, as of Jun 2025, the value is 2.21. The value appears strong and on an upward trend. It has increased from 0.19 (Mar 2025) to 2.21, marking an increase of 2.02.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: November 15, 2025, 3:20 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 108.38 | 117.93 | 129.61 | 140.56 | 149.19 | 144.59 | 111.87 | 69.24 | 86.18 | 85.95 | 59.01 | 0.00 | 0.05 |
| Expenses | 99.39 | 110.37 | 123.31 | 139.64 | 147.44 | 146.94 | 114.57 | 75.58 | 82.74 | 81.38 | 60.22 | 2.14 | 1.54 |
| Operating Profit | 8.99 | 7.56 | 6.30 | 0.92 | 1.75 | -2.35 | -2.70 | -6.34 | 3.44 | 4.57 | -1.21 | -2.14 | -1.49 |
| OPM % | 8.29% | 6.41% | 4.86% | 0.65% | 1.17% | -1.63% | -2.41% | -9.16% | 3.99% | 5.32% | -2.05% | -2,980.00% | |
| Other Income | 6.85 | 7.63 | 7.21 | 7.95 | 8.44 | 10.03 | 11.11 | 15.10 | 7.39 | 6.64 | 64.88 | 2.72 | 6.46 |
| Interest | 0.46 | 0.51 | 0.40 | 0.46 | 0.38 | 0.51 | 7.81 | 7.20 | 6.56 | 6.07 | 4.30 | 0.01 | 0.00 |
| Depreciation | 1.99 | 2.71 | 3.16 | 3.94 | 4.21 | 4.38 | 12.53 | 12.88 | 12.53 | 12.15 | 9.36 | 0.00 | 0.00 |
| Profit before tax | 13.39 | 11.97 | 9.95 | 4.47 | 5.60 | 2.79 | -11.93 | -11.32 | -8.26 | -7.01 | 50.01 | 0.57 | 4.97 |
| Tax % | 34.43% | 34.25% | 35.58% | 30.20% | 40.54% | 26.16% | -25.48% | -30.48% | 0.12% | 120.97% | 9.36% | 31.58% | |
| Net Profit | 8.78 | 7.86 | 6.42 | 3.11 | 3.32 | 2.06 | -8.89 | -7.87 | -8.27 | -15.48 | 45.32 | 0.39 | 4.53 |
| EPS in Rs | 4.72 | 4.23 | 3.45 | 1.67 | 1.78 | 1.10 | -4.74 | -4.20 | -4.41 | -8.26 | 24.18 | 0.21 | 2.42 |
| Dividend Payout % | 10.60% | 11.84% | 14.50% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 175.93% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -10.48% | -18.32% | -51.56% | 6.75% | -37.95% | -531.55% | 11.47% | -5.08% | -87.18% | 392.76% | -99.14% |
| Change in YoY Net Profit Growth (%) | 0.00% | -7.84% | -33.24% | 58.31% | -44.70% | -493.60% | 543.03% | -16.56% | -82.10% | 479.95% | -491.90% |
Fortis Malar Hospitals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -100% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | -26% |
| 5 Years: | 15% |
| 3 Years: | 27% |
| TTM: | 190% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | 7% |
| 3 Years: | 3% |
| 1 Year: | 11% |
| Return on Equity | |
|---|---|
| 10 Years: | -4% |
| 5 Years: | -11% |
| 3 Years: | -10% |
| Last Year: | 1% |
Last Updated: September 5, 2025, 3:30 pm
No data available for the Balance Sheet data table.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 13.13 | 13.03 | 16.93 | 14.49 | 14.68 | 24.39 | 12.17 | 11.02 | 9.32 | 13.50 | 0.00 | |
| Inventory Days | 4.02 | 13.24 | 35.39 | 28.37 | 22.30 | 18.04 | 22.44 | 42.32 | 39.89 | 31.71 | 0.00 | |
| Days Payable | 153.41 | 169.39 | 286.36 | 173.78 | 277.45 | 257.22 | 323.72 | 373.05 | 428.91 | 584.69 | ||
| Cash Conversion Cycle | -136.26 | -143.11 | -234.05 | -130.92 | -240.47 | -214.79 | -289.11 | -319.72 | -379.70 | -539.47 | 0.00 | |
| Working Capital Days | 187.38 | 163.79 | 126.13 | 152.64 | 131.84 | 155.53 | -55.01 | 114.55 | 21.60 | 183.80 | -8.35 | |
| ROCE % | 17.17% | 14.19% | 11.83% | 5.02% | 5.90% | 3.24% | -3.04% | -7.15% | -1.25% | -0.77% | -3.29% | 0.83% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 0.21 | 24.18 | -8.26 | -4.41 | -4.20 |
| Diluted EPS (Rs.) | 0.21 | 24.18 | -8.26 | -4.41 | -4.20 |
| Cash EPS (Rs.) | 0.20 | 29.15 | -1.78 | 2.27 | 2.67 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 16.11 | 58.36 | 34.21 | 42.72 | 47.31 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 16.11 | 58.36 | 34.21 | 42.72 | 47.31 |
| Revenue From Operations / Share (Rs.) | 0.00 | 31.46 | 45.82 | 45.94 | 36.92 |
| PBDIT / Share (Rs.) | 0.30 | 3.06 | 5.98 | 5.77 | 1.02 |
| PBIT / Share (Rs.) | 0.30 | -1.93 | -0.49 | -0.90 | -5.84 |
| PBT / Share (Rs.) | 0.30 | 26.66 | -3.74 | -4.40 | -6.03 |
| Net Profit / Share (Rs.) | 0.20 | 24.16 | -8.25 | -4.41 | -4.20 |
| NP After MI And SOA / Share (Rs.) | 0.20 | 24.16 | -8.25 | -4.41 | -4.20 |
| PBDIT Margin (%) | 0.00 | 9.74 | 13.04 | 12.56 | 2.76 |
| PBIT Margin (%) | 0.00 | -6.12 | -1.09 | -1.97 | -15.82 |
| PBT Margin (%) | 0.00 | 84.74 | -8.15 | -9.58 | -16.33 |
| Net Profit Margin (%) | 0.00 | 76.81 | -18.01 | -9.60 | -11.36 |
| NP After MI And SOA Margin (%) | 0.00 | 76.81 | -18.01 | -9.60 | -11.36 |
| Return on Networth / Equity (%) | 1.29 | 41.40 | -24.12 | -10.32 | -8.86 |
| Return on Capital Employeed (%) | 1.91 | -3.29 | -0.88 | -1.31 | -7.59 |
| Return On Assets (%) | 1.06 | 39.11 | -11.21 | -5.14 | -4.65 |
| Asset Turnover Ratio (%) | 0.00 | 0.46 | 0.57 | 0.52 | 0.38 |
| Current Ratio (X) | 5.15 | 17.68 | 2.66 | 1.56 | 2.43 |
| Quick Ratio (X) | 5.15 | 17.68 | 2.63 | 1.50 | 2.36 |
| Dividend Payout Ratio (NP) (%) | 20319.48 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 20319.48 | 0.00 | 0.00 | 0.00 | 0.00 |
| Earning Retention Ratio (%) | -20219.48 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Earning Retention Ratio (%) | -20219.48 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 56.70 | 1.34 | 1.85 | 1.65 | 0.26 |
| Interest Coverage Ratio (Post Tax) (X) | 39.43 | -1.93 | -1.55 | -0.26 | -1.04 |
| Enterprise Value (Cr.) | 119.90 | -20.82 | 80.00 | 95.58 | 90.44 |
| EV / Net Operating Revenue (X) | 0.00 | -0.35 | 0.93 | 1.11 | 1.31 |
| EV / EBITDA (X) | 207.33 | -3.62 | 7.14 | 8.83 | 47.25 |
| MarketCap / Net Operating Revenue (X) | 0.00 | 1.48 | 1.04 | 1.25 | 1.50 |
| Retention Ratios (%) | -20219.48 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price / BV (X) | 4.56 | 0.79 | 1.39 | 1.35 | 1.17 |
| Price / Net Operating Revenue (X) | 0.00 | 1.48 | 1.04 | 1.25 | 1.50 |
| EarningsYield | 0.00 | 0.51 | -0.17 | -0.07 | -0.07 |
After reviewing the key financial ratios for Fortis Malar Hospitals Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.21. This value is below the healthy minimum of 5. It has decreased from 24.18 (Mar 24) to 0.21, marking a decrease of 23.97.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.21. This value is below the healthy minimum of 5. It has decreased from 24.18 (Mar 24) to 0.21, marking a decrease of 23.97.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.20. This value is below the healthy minimum of 3. It has decreased from 29.15 (Mar 24) to 0.20, marking a decrease of 28.95.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 16.11. It has decreased from 58.36 (Mar 24) to 16.11, marking a decrease of 42.25.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 16.11. It has decreased from 58.36 (Mar 24) to 16.11, marking a decrease of 42.25.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 0.00. It has decreased from 31.46 (Mar 24) to 0.00, marking a decrease of 31.46.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 0.30. This value is below the healthy minimum of 2. It has decreased from 3.06 (Mar 24) to 0.30, marking a decrease of 2.76.
- For PBIT / Share (Rs.), as of Mar 25, the value is 0.30. This value is within the healthy range. It has increased from -1.93 (Mar 24) to 0.30, marking an increase of 2.23.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.30. This value is within the healthy range. It has decreased from 26.66 (Mar 24) to 0.30, marking a decrease of 26.36.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.20. This value is below the healthy minimum of 2. It has decreased from 24.16 (Mar 24) to 0.20, marking a decrease of 23.96.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 0.20. This value is below the healthy minimum of 2. It has decreased from 24.16 (Mar 24) to 0.20, marking a decrease of 23.96.
- For PBDIT Margin (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 10. It has decreased from 9.74 (Mar 24) to 0.00, marking a decrease of 9.74.
- For PBIT Margin (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 10. It has increased from -6.12 (Mar 24) to 0.00, marking an increase of 6.12.
- For PBT Margin (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 10. It has decreased from 84.74 (Mar 24) to 0.00, marking a decrease of 84.74.
- For Net Profit Margin (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 5. It has decreased from 76.81 (Mar 24) to 0.00, marking a decrease of 76.81.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 8. It has decreased from 76.81 (Mar 24) to 0.00, marking a decrease of 76.81.
- For Return on Networth / Equity (%), as of Mar 25, the value is 1.29. This value is below the healthy minimum of 15. It has decreased from 41.40 (Mar 24) to 1.29, marking a decrease of 40.11.
- For Return on Capital Employeed (%), as of Mar 25, the value is 1.91. This value is below the healthy minimum of 10. It has increased from -3.29 (Mar 24) to 1.91, marking an increase of 5.20.
- For Return On Assets (%), as of Mar 25, the value is 1.06. This value is below the healthy minimum of 5. It has decreased from 39.11 (Mar 24) to 1.06, marking a decrease of 38.05.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.00. It has decreased from 0.46 (Mar 24) to 0.00, marking a decrease of 0.46.
- For Current Ratio (X), as of Mar 25, the value is 5.15. This value exceeds the healthy maximum of 3. It has decreased from 17.68 (Mar 24) to 5.15, marking a decrease of 12.53.
- For Quick Ratio (X), as of Mar 25, the value is 5.15. This value exceeds the healthy maximum of 2. It has decreased from 17.68 (Mar 24) to 5.15, marking a decrease of 12.53.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 20,319.48. This value exceeds the healthy maximum of 50. It has increased from 0.00 (Mar 24) to 20,319.48, marking an increase of 20,319.48.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 20,319.48. This value exceeds the healthy maximum of 50. It has increased from 0.00 (Mar 24) to 20,319.48, marking an increase of 20,319.48.
- For Earning Retention Ratio (%), as of Mar 25, the value is -20,219.48. This value is below the healthy minimum of 40. It has decreased from 0.00 (Mar 24) to -20,219.48, marking a decrease of 20,219.48.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is -20,219.48. This value is below the healthy minimum of 40. It has decreased from 0.00 (Mar 24) to -20,219.48, marking a decrease of 20,219.48.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 56.70. This value is within the healthy range. It has increased from 1.34 (Mar 24) to 56.70, marking an increase of 55.36.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 39.43. This value is within the healthy range. It has increased from -1.93 (Mar 24) to 39.43, marking an increase of 41.36.
- For Enterprise Value (Cr.), as of Mar 25, the value is 119.90. It has increased from -20.82 (Mar 24) to 119.90, marking an increase of 140.72.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. It has increased from -0.35 (Mar 24) to 0.00, marking an increase of 0.35.
- For EV / EBITDA (X), as of Mar 25, the value is 207.33. This value exceeds the healthy maximum of 15. It has increased from -3.62 (Mar 24) to 207.33, marking an increase of 210.95.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. It has decreased from 1.48 (Mar 24) to 0.00, marking a decrease of 1.48.
- For Retention Ratios (%), as of Mar 25, the value is -20,219.48. This value is below the healthy minimum of 30. It has decreased from 0.00 (Mar 24) to -20,219.48, marking a decrease of 20,219.48.
- For Price / BV (X), as of Mar 25, the value is 4.56. This value exceeds the healthy maximum of 3. It has increased from 0.79 (Mar 24) to 4.56, marking an increase of 3.77.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. It has decreased from 1.48 (Mar 24) to 0.00, marking a decrease of 1.48.
- For EarningsYield, as of Mar 25, the value is 0.00. This value is below the healthy minimum of 5. It has decreased from 0.51 (Mar 24) to 0.00, marking a decrease of 0.51.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Unable to fetch valid data for stock valuation.Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Fortis Malar Hospitals Ltd:
- Net Profit Margin: 0%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 1.91% (Industry Average ROCE: 15.48%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 1.29% (Industry Average ROE: 14.81%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 39.43
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 5.15
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 26.4 (Industry average Stock P/E: 98.9)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 0%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Hospitals & Medical Services | Fortis Hospital, Sector 62, Mohali Punjab 160062 | secretarial.malar@malarhospitals.in http://www.fortismalarhospital.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Daljit Singh | Chairman (Non - Executive) & Non Independent Direc |
| Mr. Chandrasekar Ramasamy | Whole Time Director |
| Ms. Richa Singh Debgupta | Non Exe.Non Ind.Director |
| Ms. Shailaja Chandra | Independent Director |
| Ms. Suvalaxmi Chakraborty | Independent Director |
| Dr. Ritu Garg | Non Exe.Non Ind.Director |